Perioperative Complications After Neoadjuvant Chemotherapy With and Without Bevacizumab for Colorectal Liver Metastases

Journal of Gastrointestinal Surgery

Volumn 17, Issue 3, 2013, Pages 527-532

  Lubezky, Nir ^a,b   Winograd, Evan ^a,b   Papoulas, Michael ^a,b   Lahat, Guy ^a,b   Shacham Shmueli, Einat ^a,b   Geva, Ravit ^a,b   Nakache, Richard ^a,b   Klausner, Joseph ^a,b   Ben Haim, Menahem ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bevacizumab; Colorectal liver metastases; Neoadjuvant chemotherapy; Perioperative complications

Indexed keywords

EID: 84873750007     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-2108-y     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics. Cancer J Clin 2010 60(5): 277-300.
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on natural history. Br J Surg 1990; 77(11): 1241-6.
3. Labianca R, Beretta GD, Kildani B et al. Colon cancer. Crit Rev Oncol Hematol 2010; 74(2): 106-33.
4. Zelek L, Bugat R, Cherqui D et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research Oncology trial). Ann Oncol 2003; 14(10): 1537-42.
5. Bismuh H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224(4): 509-20.
6. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240(4): 644-57.
7. Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol 2009 12; 15(31): 3855-64.
8. Popescu I, Alexandrescu S, Croitoru A et al. Strategies to convert to resectability the initially unresectable colorectal liver metastases. Hepatogastroenterology 2009 56(91-92): 739-44.
9. Bertolini F, Malavasi N, Scarabelli L et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Can 2011 29; 104(7): 1079-84.
10. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004 3; 350(23): 2335-42.
11. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Can Inst 2007 15; 99(16): 1232-9.
12. Wu S, Kim C, Baer L et al. Bevacizumab increases risk for sever proteinuria in cancer patients. J Am Soc Nephrol 2010; 21(8): 1381-9.
13. Elice F, Rodegheiro F. Bleeding complications of antiangiogenic therapy: pathogenetic mechanism and clinical impact. Thromb Res 2010; 125 Suppl 2; S55-S57.
14. Chaundhury P, Hassanain M, Bouganim N et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal liver metastases. HPB(Oxford). 2010; 12: 37-42.
15. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. The Oncologist 2007; 12: 825-39.
16. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-9.
17. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-9.
18. Small RM, Lubezky N, Shmueli E et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009 1; 99(2): 93-8.
19. Vauthey JN, Pawlick TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic metastases. J Clin Oncol 2006; 24: 2065-2072.
20. Rubbia-Brandt L, Audard V, Satoretti P et al. Severe hepaic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-6.
21. Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24: 4983-90, 2006.
22. Tamandl D, Gruenberger B, Klinger M et al. Liver resection remains a safe procedure after neoadjuvant chemotherapy sincluding bevacizumab. A case-controlled study. Ann Surg 2010; 252: 124-130.
23. Scappaticci FA, Fehrenbacher L et al. Phase 2, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Surg Oncol. 91: 173-180, 2005.
24. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106.
25. D'Angelica M, Kornprat P, Mithat G, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14(2): 759-65.
26. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2007; 26: 5254-60.
27. Mahfud M, Breitenstein S, El-Badry AM, et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg (2010) 34: 92-100.
28. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer (2007) 110: 2761-2767.